RxDoctor Payments Data

Ala Nijim, MD

Pulmonary Disease · Longview, TXNPI 1356683189

Payments from drug & device makers

$4,571in general payments, 2019–2025

Across 261 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$788
  • Insmed, Inc.$566
  • Boehringer Ingelheim$445
  • Sanofi$250
  • Baxter Healthcare$196
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$4,45798%
  • Education$1142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,571 in reported general payments places this provider in the 55th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$142,307
Medicare patients
472
Services billed
1,867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter529$438,537
Breztri AerosphereBudesonide/Glycopyr/Formoterol122$90,937
Breo ElliptaFluticasone/Vilanterol70$34,857
EliquisApixaban19$11,066
SymbicortBudesonide/Formoterol Fumarate26$9,738
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$6,177
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,136
Advair HfaFluticasone Propion/Salmeterol14$4,390
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$3,920
Albuterol Sulfate HfaAlbuterol Sulfate159$3,832
Wixela InhubFluticasone Propion/Salmeterol15$2,982
BreynaBudesonide/Formoterol Fumarate11$1,999
Fluticasone Propionate44$1,593
Ventolin HfaAlbuterol Sulfate22$1,318
Levalbuterol Tartrate HfaLevalbuterol Tartrate17$950

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,178$479,531613 claims
AstraZenecaBreztri Aerosphere, Symbicort$788$100,675148 claims
PfizerEliquis$35$11,06619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →